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DILI

:   drug‐induced liver injury

DILIN

:   Drug‐Induced Liver Injury Network

*FTO*

:   fat mass and obesity associated

NAFLD

:   nonalcoholic fatty liver disease

SNP

:   single nucleotide polymorphism

With the application of genetic testing to contemporary medical diagnostics and practice, it has become apparent that the phenotypes of many disorders are modulated by host genetic factors. For example, the susceptibility to and progression of nonalcoholic fatty liver disease (NAFLD) have been associated with the p. I148M variant in the patatin‐like phospholipase domain‐containing protein 3 (*PNPLA3*) gene and the p. E167K variant of transmembrane 6 super family 2 (*TM6SF2*).[1](#hep41382-bib-0001){ref-type="ref"}, [2](#hep41382-bib-0002){ref-type="ref"} In contrast, susceptibility to idiosyncratic drug‐induced liver injury (DILI), a rare form of liver disease, has been associated primarily with genes that influence innate or adaptive immune responses.[3](#hep41382-bib-0003){ref-type="ref"}, [4](#hep41382-bib-0004){ref-type="ref"}

The aim of the current study was to determine whether selected single nucleotide polymorphisms (SNPs) unrelated to the human leukocyte antigen region or other immune pathways, including those associated with NAFLD, may influence development, severity, or outcomes of DILI.

Materials and Methods {#hep41382-sec-0002}
=====================

Thirteen variants previously associated with NAFLD and/or selected other liver diseases were tested in 832 Caucasian DILI cases and 10,397 Caucasian population controls (Table [1](#hep41382-tbl-0001){ref-type="table"}).[5](#hep41382-bib-0005){ref-type="ref"} DILI cases were attributed to multiple agents (177 individual drugs), with 56 cases due to herbal/dietary supplement products. All cases had DILI Network (DILIN) causality scores equal to or higher than probable (judged 51%‐100% likely due to a drug). None of the subjects from DILIN had been enrolled as acute cases (within 14 days of onset). Eight variants were imputed from the most recent genome‐wide association study,[5](#hep41382-bib-0005){ref-type="ref"} and four additional variants were directly genotyped only in DILI cases, except for the hydroxysteroid dehydrogenase 17B13 (HSD17B13) splice variant, which was typed only in a subset of the DILI cases (n = 384). For the latter variants, the allele frequencies for European (non‐Finnish) control samples in the Gnomad database were used (<https://gnomad.broadinstitute.org/>).

###### 

SNPs Investigated in Dilin Caucasian DILI Cases and Population Controls

  Gene Name                                           Genetic Variant                                       Coding DNA Change   Amino Acid Change                                                                      Putative Effect of Variant in NAFLD                                                                            DILI Case MAF   Control MAF   *P*
  --------------------------------------------------- ----------------------------------------------------- ------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------- ------------- -------
  *PNPLA3*                                            rs738409                                              444C\>G             I148M                                                                                  Increased hepatocyte triglyceride content                                                                      21.1%           23.4%         0.5
  rs6006460[\*](#hep41382-note-0004){ref-type="fn"}   1531G\>T                                              S453I               Lower than average hepatic triglyceride accumulation                                   0.06%                                                                                                          0.02%           0.2           
  *TM6SF2*                                            rs58542926                                            499A\>G             E167K                                                                                  Elevated AST/ALT, increased hepatic triglyceride levels, decreased serum cholesterol                           6.9%            7.5%          0.37
  rs10401969                                          613+80A\>G                                            Intron              Lower hepatic TM6SF2 mRNA levels correlate with larger hepatocellular lipid droplets   6.9%                                                                                                           7.7%            0.2           
  *LIPA*                                              rs116928232[\*](#hep41382-note-0004){ref-type="fn"}   894G\>A             E8SJM                                                                                  Cholesterol ester storage disease often resulting in fibrosis→cirrhosis                                        0.1%            0.1%          1
  *IFNL4*                                             rs12979860[\*](#hep41382-note-0004){ref-type="fn"}    151‐152G\>A         Intron                                                                                 Increased degree of hepatic inflammation and fibrosis                                                          32.3%           32.0%         0.9
  *HFE*                                               rs1800562                                             845G\>A             C282Y                                                                                  Increased hepatic iron uptake, associated with greater NAFLD risk/severity                                     6.0%            5.5%          0.74
  rs1799945                                           187C\>G                                               H63D                Increased hepatic iron uptake, associated with greater NAFLD risk/severity             15.3%                                                                                                          15.9%           0.8           
  *HMOX1*                                             rs2071746[\*](#hep41382-note-0004){ref-type="fn"}     --413A\>T           Affects promoter                                                                       Higher HMOX1 activity correlated with less frequent and less severe NAFLD                                      42.7%           43.5%         0.9
  *FTO*                                               rs1421085                                             46‐43098T\>C        Affects repressor                                                                      Adipocytic phenotype shift from beige (energy dissipating) to white (energy storing)                           38.2%           41.7%         0.005
  *GNPAT*                                             rs11558492                                            1556A\>G            D519G                                                                                  Worsened iron overload in patients with *HFE* genetic variations                                               21.1%           23.3%         0.7
  *SERPINA1*                                          rs28929474                                            1096G\>A            E342K                                                                                  Associated with deficiency of alpha‐1 antitrypsin and with increased risk of liver diseases                    2%              2%            0.73
  *HSD17B13*                                          rs72613567[†](#hep41382-note-0005){ref-type="fn"}     4:88231392;T\>TA    Splice variant                                                                         Associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis   28%             27%           0.52

Variants directly genotyped only in DILI cases;

Variant genotyped only in a subset of the DILI cases (n = 384).

Abbreviations: ALT, alanine, aminotransferase; AST, aspartate aminotransferase; GNPAT, glyceroneophophate O‐acyltransferase; HFE, homeostatic iron regulator; HMOX1, heme oxygenase 1; HSD17B13, hydroxysteroid 17‐beta dehydrogenase 13; IFNL4, interferon lambda 4; LIPA, lipase A, lysosomal acid type 1; MAF, minor allele frequency; mRNA, messenger RNA; PNPLA3, patatin‐like phospholipase domain‐containing protein 3; SERPINA1, serpin peptidase inhibitor, clade A, member 1; TM6SF2, transmembrane 6 super family 2.
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The DILI cases were also categorized by severity and chronic DILI. Chronic DILI was defined as evidence of ongoing liver injury 6 months after DILI onset, as described.[3](#hep41382-bib-0003){ref-type="ref"}, [5](#hep41382-bib-0005){ref-type="ref"} The significance was tested by linear regression or logistic regression, depending on the nature of the trait. For genotyped variants and binary traits, associations were compared to European control samples listed in the Gnomad database and by Fisher\'s exact test.

Any variant that passed the Bonferroni threshold of *P* \< 0.0004 ($\frac{0.05}{13}$) was considered a significant association. Follow‐up analyses were done for the most strongly associated variants by testing in an independent Caucasian cohort of 974 DILI cases from the International DILI Consortium[5](#hep41382-bib-0005){ref-type="ref"} and in African Americans (169 DILIN cases versus 1,314 controls) and Hispanic cohorts (109 DILIN cases and 718 controls).[5](#hep41382-bib-0005){ref-type="ref"}

Results {#hep41382-sec-0003}
=======

None of the variants proved to be significantly associated with DILI as phenotype (Table [1](#hep41382-tbl-0001){ref-type="table"}) nor with any of the selected severity traits (Supporting Table [S1](#hep41382-sup-0001){ref-type="supplementary-material"}). Among the variants studied, rs1421085, found in the fat mass and obesity associated (*FTO*) gene, showed a marginal protective effect (odds ratio, 0.8; 95% confidence interval, 0.77‐0.95; *P* = 0.005, with similar trends also in Hispanic and African‐American cohorts), but Caucasian replication cases showed a higher frequency of the variants (Supporting Table [S1](#hep41382-sup-0001){ref-type="supplementary-material"}).

Discussion {#hep41382-sec-0004}
==========

None of the genetic polymorphisms tested were significantly associated with the risk of development, severity, or outcome of DILI. These data suggest that SNPs implicated in common liver diseases, such as NAFLD, do not play a substantial role in DILI pathogenesis across agents. However, it remains possible that these variants could be involved with DILI risk or outcome due to a single drug, but this will require the evaluation of larger numbers of *bona fide* cases due to specific drugs. In addition, rare variants may play a role in DILI pathogenesis, but additional studies using whole exome or genome testing are required.

Supporting information
======================
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Click here for additional data file.
